Loading...
Use of long-acting injectable antiretroviral agents for human immunodeficiency Virus: A review
Ariyo, Olumuyiwa E. Jones, Christopher E.
Ariyo, Olumuyiwa E.
Jones, Christopher E.
Advisors
Editors
Other Contributors
EPub Date
Publication Date
2021-11-23
Submitted Date
Collections
Files
Loading...
Article - AAM
Adobe PDF, 2.19 MB
Other Titles
Abstract
The development of potent antiretroviral drugs has significantly reduced morbidity and mortality associated with human immunodeficiency virus infection, however, the effectiveness of these medications depends upon consistent daily oral intake. Non-adherence can lead to the emergence of resistance, treatment failure and disease progression. This has necessitated the development of long-acting antiretroviral formulations administrable via an infrequent dosing regimen. Long-acting injectable forms of cabotegravir and rilpivirine have reached various stages in clinical trials both for the treatment and prevention of HIV. Other long-acting agents are at various stages of development. This review evaluates the current research on the development of long-acting injectable antiretroviral agents for the treatment and prevention of HIV.
Citation
Ariyo, O. E., & Jones, C. E. (2022). Use of long-acting injectable antiretroviral agents for human immunodeficiency virus: A review. Journal of Clinical Virology, 146, Article number 105032. https://doi.org/10.1016/j.jcv.2021.105032
Publisher
Elsevier
Journal
Journal of Clinical Virology
Research Unit
DOI
10.1016/j.jcv.2021.105032
PubMed ID
PubMed Central ID
Type
Article
Language
Description
Series/Report no.
ISSN
1386-6532